FDA Exploring Over-the-Counter Access to Vaginal Estrogen
The FDA says it is working with sponsors to explore over-the-counter availability of vaginal estrogen. Here’s what that could mean for vaginal dryness and other menopause symptoms.
The FDA says it is working with sponsors to explore over-the-counter availability of vaginal estrogen. Here’s what that could mean for vaginal dryness and other menopause symptoms.
HHS announced that the FDA approved updated labeling for three more estradiol patch products, removing boxed warning statements, and gave an update on hormone therapy supply and access.
Hot flashes are the #1 menopause complaint, yet millions of women can’t — or prefer not to — use hormone therapy.
That’s why the newest data on Cendifensine is getting so much attention.
In a historic move, the FDA has requested the removal of the black box warning from hormone therapy used for menopause. Experts say this long-overdue update reflects modern science—and could help women reclaim access to safe, effective symptom relief.
The FDA has approved Lynkuet (Elinzanetant), a groundbreaking non-hormonal medication that targets the brain pathways behind hot flashes. For women who can’t or prefer not to use hormone therapy, this represents a major step forward in menopause care.
A year-long study of Elinzanetant (Lynkuet) reveals lasting relief from hot flashes and improved sleep without hormones. Here’s what you need to know about this breakthrough non-hormonal option.
UK approves first testosterone cream for postmenopausal women—sparking hope for future FDA approval in the U.S.
Could a weekly pill shift the menopause timeline? Researchers are exploring how one drug might change the future of women’s health.